ABSTRACT
BACKGROUND: Chronic idiopathic urticaria is a clinic entity that is manifested by wheals of more than six weeks of evolution, without identification of the causing agent, and sometimes resistant to conventional treatment. There are improvements with leukotriene receptor antagonists. OBJECTIVE: To evaluate the clinical efficacy of montelukast and desloratadine individually and combined, compared with hydroxicine. PATIENTS AND METHODS: The trial included 40 subjects with chronic idiopathic urticaria referred from the outpatient allergy service. They were randomly divided into four groups to receive: hydoxicine, montelukast, montelukast plus desloratadine, and desloratadine alone during six weeks. The assessments compared the first and sixth weeks. RESULTS: All therapeutic options are effective, with statistical significance, highlighting that the new therapeutic modes are safe and have better resolution of lesions and symptoms. CONCLUSIONS: All the alternatives are viable, considering they are adjusted to each patient, adverse symptoms, socio-economic status and clinical severity.